BOD

Pamela D. Garzone, Ph.D.

Pamela D. Garzone, age 71, joined our board of directors in April 2023. Dr. Garzone has served as the Chief Development Officer at Anixa Biosciences, Inc., a company focused on oncology and infectious diseases, since September 2021. She currently is an independent director for Centivax and Temple Therapeutics, private biotechnology companies and as a scientific advisor to National Foundation of Cancer Research, a non-profit organization supporting cancer research. Prior to joining Anixa, Dr. Garzone served as the Chief Medical Officer at Calibr, a division of the Scripps Research Institute from May 2019 to May 2021. From May 2009 through May 2019, Dr. Garzone served as the Vice President, Group Asset Team Lead focused on early oncology clinical research at Pfizer Inc. Dr. Garzone earned a B.S. degree in pharmacy from Purdue University and an M.S. in pharmacy practice and Ph.D. in clinical science from the University of Pittsburgh.  Dr. Garzone’s extensive knowledge of the biopharmaceutical industry in general, and drug development in particular, with operational and strategic expertise, makes her well qualified to serve on our board of directors.